ClinicalTrials.gg
WithdrawnNCT02799758Updated May 10, 2021

Efficacy & Long-term Safety Comparison Study of NK-104-CR & Livalo® IR With Primary Hyperlipidemia or Mixed Dyslipidemia

A Phase 3 interventional study of NK-104-CR and Livalo® IR in Hyperlipidemia and Dyslipidemia, sponsored by Kowa Research Institute, Inc.. Withdrawn at 69 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-05-10.

Sponsored by Kowa Research Institute, Inc. (part of Kowa Company, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 338 studies in Hyperlipidemias with a site in United States — 30 open to participants now, 45 under way, 10 of them phase 3. Hyperlipidemias · United States.

Enrollment
302nd of 306
0 · median 120
Started
2016
with 15 others
Phase 3
73 of 338
3 open now
Registered
220th of 338
by date

Among the 338 studies in Hyperlipidemias with a site in United States, this one is the 302nd largest by enrollment of the 306 interventional ones that give a count, is one of 16 that started in 2016, is one of 73 in phase 3, and was the 220th registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

30 of the 338 studies in Hyperlipidemias with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 338 studies in Hyperlipidemias with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate the superior efficacy of NK-104-CR 8 mg daily compared to Livalo® IR 4 mg daily on fasting serum low-density lipoprotein cholesterol (LDL-C) reduction and to evaluate the comparative safety of NK-104-CR 8 mg daily to Livalo® IR 4 mg daily after long-term treatment

03

Conditions studied

  • Hyperlipidemia
  • Dyslipidemia
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients with primary hyperlipidemia or mixed dyslipidemia
  • Patients for whom lipid-lowering therapy is indicated according to NCEP ATPIII
  • Patients who are naïve to statin or who are able to safely discontinue the use of all lipid-lowering agents for 4 weeks before randomization and throughout study participation

Exclusion criteria

Exclusion Criteria:

  • Homozygous familial hypercholesterolemia;
  • Any conditions which may cause secondary dyslipidemia.
  • Newly diagnosed or poorly controlled diabetes mellitus as defined by >9%
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    NK-104-CR

    NK-104-CR 8 mg tablet and Placebo (for Livalo® IR 4 mg tablet) orally once daily for 52 weeks.

    Drug: NK-104-CR · Drug: Placebo (for Livalo® IR)

  • Active comparator
    Livalo® IR

    Livalo® IR 4 mg tablet and Placebo (for NK-104-CR 8 mg tablet) orally once daily for 52 weeks.

    Drug: Livalo® IR · Drug: Placebo (for NK-104-CR)

Interventions

  • NK-104-CR 8 mg for 52 weeks

  • Livalo® IR 4 mg daily for 52 weeks

  • DrugPlacebo (for NK-104-CR)

    NK-104-CR 8 mg placebo for 52 weeks

  • DrugPlacebo (for Livalo® IR)

    Livalo® IR 4 mg placebo for 52 weeks

06

What researchers measure

Primary outcomes

  1. Percent change in Low-density lipoprotein cholesterol (LDL-C)

    Time frame: Baseline to Week 12 endpoint

07

Study locations

69 sites
  • Foley, Alabama, United States
  • Huntsville, Alabama, United States
  • Montgomery, Alabama, United States
  • Muscle Shoals, Alabama, United States
  • Little Rock, Arkansas, United States
  • Greenbrae, California, United States
  • Huntington Park, California, United States
  • Lomita, California, United States
  • Long Beach, California, United States
  • Los Angeles, California, United States
  • Santa Ana, California, United States
  • Spring Valley, California, United States
  • Tustin, California, United States
  • Walnut Creek, California, United States
  • Milford, Connecticut, United States
  • Atlantis, Florida, United States
  • Cooper City, Florida, United States
  • Coral Springs, Florida, United States
  • Fleming Island, Florida, United States
  • Jacksonville, Florida, United States
  • Miami, Florida, United States
  • Oviedo, Florida, United States
  • Dawsonville, Georgia, United States
  • Macon, Georgia, United States
  • Suwanee, Georgia, United States
  • Addison, Illinois, United States
  • Chicago, Illinois, United States
  • Gurnee, Illinois, United States
  • Morton, Illinois, United States
  • Evansville, Indiana, United States
  • Topeka, Kansas, United States
  • Louisville, Kentucky, United States
  • Owensboro, Kentucky, United States
  • Oxon Hill, Maryland, United States
  • Biloxi, Mississippi, United States
  • Olive Branch, Mississippi, United States
  • Jefferson City, Missouri, United States
  • Saint Louis, Missouri, United States
  • Omaha, Nebraska, United States
  • Manlius, New York, United States
  • High Point, North Carolina, United States
  • Salisbury, North Carolina, United States
  • Wilmington, North Carolina, United States
  • Winston-Salem, North Carolina, United States
  • Fargo, North Dakota, United States
  • Cincinnati, Ohio, United States
  • Columbus, Ohio, United States
  • Franklin, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Medford, Oregon, United States
  • Beaver, Pennsylvania, United States
  • Harleysville, Pennsylvania, United States
  • Jersey Shore, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Moncks Corner, South Carolina, United States
  • Simpsonville, South Carolina, United States
  • Summerville, South Carolina, United States
  • Austin, Texas, United States
  • Houston, Texas, United States
  • Katy, Texas, United States
  • Plano, Texas, United States
  • Round Rock, Texas, United States
  • San Antonio, Texas, United States
  • Salt Lake City, Utah, United States
  • Richmond, Virginia, United States
  • Suffolk, Virginia, United States
  • Seattle, Washington, United States
  • Kenosha, Wisconsin, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2016, a primary completion of Jul 2017 and a completion of Nov 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2016
First posted
Jun 15, 2016
Start
Feb 2016
Primary completionEst.
Jul 2017
CompletionEst.
Nov 2017
Last update
May 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02799758
Responsible party
Sponsor
First posted
Jun 15, 2016
Start date
Feb 2016
Primary completion
Jul 2017 (estimated)
Completion
Nov 2017 (estimated)
Last update
May 10, 2021

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pitavastatin

Start the discussion